Theravance Biopharma, Inc.

NasdaqGM:TBPH Stock Report

Market Cap: US$445.0m

Theravance Biopharma Management

Management criteria checks 3/4

Theravance Biopharma's CEO is Rick Winningham, appointed in Jun 2014, has a tenure of 10.58 years. total yearly compensation is $4.32M, comprised of 24.3% salary and 75.7% bonuses, including company stock and options. directly owns 3.88% of the company’s shares, worth $17.26M. The average tenure of the management team and the board of directors is 2.6 years and 6.9 years respectively.

Key information

Rick Winningham

Chief executive officer

US$4.3m

Total compensation

CEO salary percentage24.3%
CEO tenure10.6yrs
CEO ownership3.9%
Management average tenure2.6yrs
Board average tenure6.9yrs

Recent management updates

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Recent updates

With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For

Nov 12
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For

We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Jul 16
We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

CEO Compensation Analysis

How has Rick Winningham's remuneration changed compared to Theravance Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$49m

Jun 30 2024n/an/a

-US$46m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$4mUS$1m

-US$55m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$75m

Dec 31 2022US$6mUS$1m

-US$93m

Sep 30 2022n/an/a

-US$136m

Jun 30 2022n/an/a

-US$196m

Mar 31 2022n/an/a

-US$226m

Dec 31 2021US$4mUS$1m

-US$265m

Sep 30 2021n/an/a

-US$266m

Jun 30 2021n/an/a

-US$264m

Mar 31 2021n/an/a

-US$275m

Dec 31 2020US$7mUS$1m

-US$295m

Sep 30 2020n/an/a

-US$285m

Jun 30 2020n/an/a

-US$270m

Mar 31 2020n/an/a

-US$247m

Dec 31 2019US$6mUS$984k

-US$236m

Sep 30 2019n/an/a

-US$221m

Jun 30 2019n/an/a

-US$222m

Mar 31 2019n/an/a

-US$223m

Dec 31 2018US$3mUS$957k

-US$216m

Compensation vs Market: Rick's total compensation ($USD4.32M) is above average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.

CEO

Rick Winningham (64 yo)

10.6yrs

Tenure

US$4,318,531

Compensation

Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022. He serves as Director at Rivus Pharmaceuticals, Inc. since 2024. He has been Lead Independent Di...

Leadership Team

NamePositionTenureCompensationOwnership
Rick Winningham
CEO & Director10.6yrsUS$4.32m3.88%
$ 17.3m
Aziz Sawaf
Senior VP & CFO2yrsUS$1.39m0.64%
$ 2.8m
Stuart Knight
Senior VP of IT&I and Chief Information Officerno datano datano data
Gail Cohen
Vice President of Corporate Communications & Investor Relationsno datano datano data
Brett Grimaud
Senior VP2.6yrsno data0.68%
$ 3.0m
Rhonda Farnum
Chief Business Officer and Senior VP of Commercial & Medical Affairs3.1yrsUS$942.81k0.64%
$ 2.8m
Stacy Pryce
Senior VP & Chief Strategy Officer2.3yrsno datano data
Aine Miller
Senior VP of Development & Head of Ireland Officeno datano data0.31%
$ 1.4m

2.6yrs

Average Tenure

54.5yo

Average Age

Experienced Management: TBPH's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rick Winningham
CEO & Director11.5yrsUS$4.32m3.88%
$ 17.3m
Eran Broshy
Independent Director10.6yrsUS$205.14k0.14%
$ 633.7k
Deepika Pakianathan
Independent Director4.5yrsUS$207.68k0.096%
$ 429.1k
Dean Mitchell
Lead Independent Director10.6yrsUS$211.73k0.16%
$ 729.0k
James Kelly
Independent Director1.8yrsUS$43.10kno data
Donal O'Connor
Independent Director9.3yrsUS$195.80k0.13%
$ 575.2k
Susannah Gray
Independent Chairman1.9yrsUS$346.47k0.064%
$ 285.0k
Laurie Smaldone Alsup
Independent Director6.9yrsUS$197.68k0.13%
$ 582.2k
Jeremy Grant
Independent Director1.1yrsUS$168.36k0.045%
$ 201.9k

6.9yrs

Average Tenure

64.5yo

Average Age

Experienced Board: TBPH's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 03:32
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Theravance Biopharma, Inc. is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Tazeen AhmadBofA Global Research
Julian HarrisonBTIG